Japan Tissue Engineering Co (TSE:7774) ROCE % : 0.00% (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Japan Tissue Engineering Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Japan Tissue Engineering Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 0.00%.

Japan Tissue Engineering Co ROCE % Historical Data

The historical data trend for Japan Tissue Engineering Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Japan Tissue Engineering Co ROCE % Chart

Japan Tissue Engineering Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

-3.01

-6.28

-7.17

-11.49

2.39

Japan Tissue Engineering Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24
ROCE %	Get a 7-Day Free Trial															0.95	-1.68	-2.75	13.04	-

Japan Tissue Engineering Co ROCE % Calculation

Japan Tissue Engineering Co's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	144.512	/	( ( (6883.32 - 911.246)	+	(6988.774 - 873.531) )	/ 2 )
	=	144.512	/	( (5972.074	+	6115.243)	/ 2 )
	=	144.512	/	6043.6585
	=	2.39 %

Japan Tissue Engineering Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	0	/	( ( (6988.774 - 873.531)	+	(6487.21 - 590.283) )	/ 2 )
	=	0	/	( ( 6115.243	+	5896.927 )	/ 2 )
	=	0	/	6006.085
	=	0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Japan Tissue Engineering Co (TSE:7774) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Japan Tissue Engineering Co ROCE % Related Terms

Thank you for viewing the detailed overview of Japan Tissue Engineering Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Japan Tissue Engineering Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Japan Tissue Engineering Co Ltd (TSE:7774) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6-209-1 Miyakitadori, Gamagori, Aichi, JPN, 443-0022

Website

https://www.jpte.co.jp

Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.

Japan Tissue Engineering Co Headlines

No Headlines